Syn2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[^1]
| Synapsin II |
|---|
| Gene Symbol | SYN2 |
| Full Name | Synapsin II |
| Chromosome | 3p25.2 |
| NCBI Gene ID | 6854 |
| OMIM | 185600 |
| Ensembl ID | ENSG00000153147 |
| UniProt ID | Q9UQ88 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Epilepsy, Schizophrenia, Autism |
SYN2 (Synapsin II) is a neuronal phosphoprotein that plays essential roles in synaptic vesicle dynamics, neurotransmitter release, and synaptic plasticity. It is a member of the synapsin family (SYN1, SYN2, SYN3) and is primarily expressed in presynaptic terminals of neurons throughout the brain. Synapsin II, along with other synapsins, is critical for maintaining synaptic vesicle pools and regulating the kinetics of neurotransmitter release, making it fundamental to normal brain function and vulnerable in neurodegenerative diseases.
- Chromosomal location: 3p25.2
- Gene family: Synapsin family
- Alternative splicing: Multiple isoforms (SYN2A, SYN2B)
- SYN2A: Longer isoform, 706 amino acids
- SYN2B: Shorter isoform, 513 amino acids
¶ Domain Organization
- N-terminal domain: Membrane binding
- Central region: Phosphorylation sites
- C-terminal domain: Protein-protein interactions
- Phosphorylation: Multiple serine sites (PKA, CaMKII)
- Alternative splicing: Generates functional variants
Synapsin II orchestrates the synaptic vesicle lifecycle:
- Vesicle clustering: Maintains reserve pool at terminals
- Vesicle tethering: Links vesicles to cytoskeleton
- Release modulation: Regulates release probability
- Recycling: Facilitates vesicle reformation
| Kinase |
Site |
Effect |
| PKA |
Ser9, Ser443 |
Dissociates from vesicles |
| CaMKII |
Multiple sites |
Activity-dependent release |
| MAPK |
Ser428 |
Long-term plasticity |
- Synapsin I/III: Functional redundancy
- Synaptophysin: Vesicle organization
- CSPα: Chaperone function
| Region |
Expression |
Notes |
| Hippocampus |
Very High |
CA1-CA3, dentate gyrus |
| Cerebral Cortex |
Very High |
All layers |
| Cerebellum |
High |
Granule cells |
| Basal Ganglia |
Moderate |
Striatum |
| Brainstem |
Moderate |
Motor nuclei |
- Presynaptic terminals
- Synaptic vesicles
- Cytoskeleton-associated
- Downregulation: Significant reduction in AD brain
- Synaptic loss: Correlates with cognitive decline
- Mechanisms: Transcriptional dysregulation
- Biomarker potential: CSF synapsin II
- Reduced expression: In substantia nigra
- α-Synuclein interactions: Pathological links
- Dopaminergic terminals: Vulnerability
- Mutations: Associated with seizure disorders
- Altered dynamics: Affects release probability
- Therapeutic target: Modulators in development
- Schizophrenia: Altered expression
- Autism: Rare variants identified
- Bipolar disorder: Genetic associations
- Synapsin modulators: Small molecule approaches
- Gene therapy: AAV-mediated expression
- Neuroprotective strategies: Preserve synaptic function
- CSF synapsin II measurement
- Disease progression monitoring
- Structural studies: Domain function
- Therapeutic development: Targeted approaches
- Genetics: Variant analysis
- Biomarkers: Clinical utility
- Animal models: Knockout studies
- SYN2 knockout: Viable with subtle deficits
- Double knockouts: Synapsin redundancy
- Transgenic: Disease models
The study of Syn2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.